Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.